Media coverage about AstraZeneca (NYSE:AZN) has trended somewhat positive recently, InfoTrie reports. The research group rates the sentiment of media coverage by analyzing more than 6,000 blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. AstraZeneca earned a news sentiment score of 1.52 on their scale. InfoTrie also assigned media stories about the company an news buzz score of 2 out of 10, indicating that recent media coverage is very unlikely to have an effect on the company’s share price in the next several days.
These are some of the news headlines that may have impacted AstraZeneca’s analysis:
- US orders 300M doses of AstraZeneca’s coronavirus vaccine – New York Post (nypost.com)
- AstraZeneca-Oxford trial COVID vaccine moves to crucial phase with $1 billion in U.S. backing – KLFY (klfy.com)
- Chinese Covid-19 Vaccine Trial Data Are a Good Sign for J&J and AstraZeneca’s Efforts – Barron’s (barrons.com)
- US Secures 300 Million Doses of Potential AstraZeneca COVID-19 Vaccine – Voice of America (voanews.com)
- Somewhat Favorable Media Coverage Very Unlikely to Impact AstraZeneca (NYSE:AZN) Stock Price (americanbankingnews.com)
Shares of NYSE:AZN opened at $55.22 on Friday. The company has a market capitalization of $145.08 billion, a PE ratio of 93.59, a price-to-earnings-growth ratio of 1.68 and a beta of 0.56. The company has a debt-to-equity ratio of 1.32, a current ratio of 0.75 and a quick ratio of 0.57. The business has a fifty day moving average price of $50.01 and a two-hundred day moving average price of $48.29. AstraZeneca has a 1 year low of $36.15 and a 1 year high of $57.44.
Several equities research analysts recently issued reports on the company. Barclays reiterated an “overweight” rating on shares of AstraZeneca in a report on Monday, April 27th. Morgan Stanley reiterated an “equal weight” rating on shares of AstraZeneca in a report on Wednesday, May 6th. ValuEngine upgraded AstraZeneca from a “sell” rating to a “hold” rating in a report on Tuesday, February 4th. Cowen reiterated a “buy” rating and set a $55.00 price target on shares of AstraZeneca in a report on Friday, February 28th. Finally, Argus upped their price target on AstraZeneca from $54.00 to $60.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company’s stock. AstraZeneca has a consensus rating of “Hold” and a consensus price target of $54.67.
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Read More: What is Elliott Wave theory?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.